The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

Exclusion Criteria

• •1. Symptoms deemed by the study Investigator to be caused exclusively by irreversible neuronal damage from prior stroke or neurosurgical instrumentation
• •2. History of cranial irradiation or surgical/radiosurgical treatment of the primary symptomatic CCM lesion
• •3. Pregnant or breast feeding
• •4. Be unable or unwilling to participate in MRI assessments (e.g., claustrophobia, metal implant or implanted cardiac pacemaker)
• •5. Liver dysfunction or active liver disease as defined by baseline serum transaminases \>2x upper limit of normal (ULN)
• •6. Have moderately or severely impaired renal function (estimated glomerular filtration rate \[eGFR\] \<60ml/min) or active renal disease or have previously received a kidney transplant
• •7. Have had a previous diagnosis of skeletal muscle disorders (myopathy) of any cause or have a baseline creatine kinase level \> 5x ULN
• •8. History of alcohol or substance abuse within 1 year prior to screening
• •9. Clinically significant laboratory abnormality
• •10. Have had an intracerebral hemorrhage within 3 months of screening or any brain surgery within 6 months of screening (not including the primary symptomatic CCM lesion)